Brain Tumors

Supratentorial Craniotomy

Survival: Supratentorial Craniotomy

2017 – 2021

The 30- and 180-day survival rates were 99% and 96%, respectively, for 2021.

Supratentorial Craniotomy: Inpatient Mortality

2017 – 2021

ᵃThe 3M™ All Patient Refined Diagnosis Related Groups (APR-DRG) Classification System is used for adjusting data for severity of illness and risk of mortality.

Inpatient mortality remained lower than expected, continuing the trend during the past 5 years. N = number of supratentorial craniotomies performed for brain tumor per year. For 2021 the inpatient mortality was 0.42% while the expected mortality was 10.44%.

Supratentorial Craniotomy: Length of Stay

2017 – 2021

LOS = length of stay

ᵃThe 3M™ All Patient Refined Diagnosis Related Groups (APR-DRG) Classification System is used for adjusting data for severity of illness and risk of mortality.

Average length of stay remained below target, continuing the trend during the past 5 years.

Supratentorial Craniotomy for Glioma

2017 – 2021

The 30- and 180-day survival rates for supratentorial craniotomy for glioma were 99% and 93%, respectively, for 2021.

Supratentorial Craniotomy for Meningioma

2017 – 2021

Both the 30- and 180-day survival rates for supratentorial craniotomy for meningioma were 99% for 2021.

Supratentorial Craniotomy for Metastasis

2017 – 2021

The 30- and 180-day survival rates for supratentorial craniotomy for brain metastasis were 100% and 88%, respectively, for 2021.